Foghorn Therapeutics, Inc. (FHTX)
1.88
+0.03
(+1.62%)
USD |
NASDAQ |
Oct 19, 15:47
Foghorn Therapeutics Enterprise Value : -15.86M for Oct. 16, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 16, 2026 | -15.86M |
| October 15, 2026 | -13.51M |
| October 14, 2026 | -15.86M |
| October 13, 2026 | -15.86M |
| October 12, 2026 | -9.987M |
| October 09, 2026 | -7.051M |
| October 08, 2026 | -7.638M |
| October 07, 2026 | -1.767M |
| October 06, 2026 | -8.813M |
| October 05, 2026 | -7.051M |
| October 02, 2026 | -5.877M |
| October 01, 2026 | 46.97M |
| September 30, 2026 | 85.13M |
| September 29, 2026 | 82.19M |
| September 28, 2026 | 82.19M |
| September 25, 2026 | 81.02M |
| September 24, 2026 | 86.89M |
| September 23, 2026 | 102.74M |
| September 22, 2026 | 124.47M |
| September 21, 2026 | 119.18M |
| September 18, 2026 | 118.60M |
| September 17, 2026 | 122.12M |
| September 16, 2026 | 120.36M |
| September 15, 2026 | 117.42M |
| September 14, 2026 | 131.51M |
| Date | Value |
|---|---|
| September 11, 2026 | 135.04M |
| September 10, 2026 | 139.15M |
| September 09, 2026 | 149.72M |
| September 08, 2026 | 159.11M |
| September 04, 2026 | 164.39M |
| September 03, 2026 | 161.46M |
| September 02, 2026 | 179.07M |
| September 01, 2026 | 209.60M |
| August 31, 2026 | 212.54M |
| August 28, 2026 | 227.81M |
| August 27, 2026 | 240.72M |
| August 26, 2026 | 268.32M |
| August 25, 2026 | 277.71M |
| August 24, 2026 | 278.89M |
| August 21, 2026 | 290.63M |
| August 20, 2026 | 287.11M |
| August 19, 2026 | 290.04M |
| August 18, 2026 | 271.84M |
| August 17, 2026 | 271.25M |
| August 14, 2026 | 243.07M |
| August 13, 2026 | 256.58M |
| August 12, 2026 | 265.38M |
| August 11, 2026 | 262.45M |
| August 10, 2026 | 241.90M |
| August 07, 2026 | 231.92M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 7.664B |
| Oncolytics Biotech, Inc. | 58.41M |
| Sangamo Therapeutics, Inc. | 37.40M |
| Sarepta Therapeutics, Inc. | 2.064B |
| Anixa Biosciences, Inc. | 77.38M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -7.191M |
| Revenue (Quarterly) | 16.07M |
| Total Expenses (Quarterly) | 23.26M |
| EPS Diluted (Quarterly) | -0.1018 |
| Gross Profit Margin (Quarterly) | 98.76% |
| Profit Margin (Quarterly) | -44.74% |
| Earnings Yield | -54.33% |
| Normalized Earnings Yield | -50.45 |